Luminary Medical

Luminary Therapeutics is a clinical-stage biotechnology company focused on developing next-generation cell therapies for cancer and autoimmune diseases. The company specializes in the development of chimeric antigen receptor (CAR) T-cell therapies, utilizing both alpha-beta and gamma-delta T-cell platforms to overcome the limitations of current treatments. Their lead program targets the B-cell activating factor receptor (BAFF-R), offering a novel approach for patients who have relapsed after traditional CD19-targeted therapies. By leveraging advanced engineering techniques, Luminary aims to provide more durable and effective treatment options for a broad range of hematologic and solid tumors.